PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders

Status Recruiting

Clinical Trial Summary

This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of sofosbuvir, ledipasvir and sofosbuvir metabolite (GS-331007) in HCV infected children with hematological Disorders. to develop predictive pharmacokinetic model for the 3 moieties in the studied population. In this study, patients in both treatment groups will receive 12 weeks of treatment with a fixed-dose combination tablet containing 400 mg of sofosbuvir and 90 mg of ledipasvir(SOF/LED) orally, once daily with food.

Clinical Trial Description

In this study, patients in both treatment groups will receive 12 weeks of treatment with a fixed-dose combination tablet containing 400 mg of sofosbuvir and 90 mg of ledipasvir(SOF/LED) orally, once daily with food, as prescribed by the attending physician. Twelve eligible HCV-infected patients with hematological disorder and 12 matching HCV control patients without haematological disorder or comorbidities will be enrolled in the study. At baseline, careful history of the recruited patients including demographic characteristics (age, height, weight, and gender), comorbidities, medication history, familial history, social history, blood transfusion history, and baseline laboratory tests will be documented. The baseline laboratory tests will include renal function tests (serum creatinine), liver function tests (bilirubin, albumin, AST, and ALT), international normalised ratio (INR), alpha fetoprotein (AFP), complete blood count (CBC), degree of liver fibrosis by Fibroscan,viral load by PCR and HCV genotype Follow-up will be done for all participants at baseline, after 10 days of treatment for the evaluation of the steady state PK parameters of SOF/LED in those patients, after 12 weeks of treatment, and after 12 weeks from the end of treatment. For a total of 4 follow-up visits. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04353986
Study type	Interventional
Source	Ain Shams University
Contact	Manal H El-Sayed, M.D.
Phone	01227461120
Email	manalhelsayed@yahoo.co.uk
Status	Recruiting
Phase	Phase 3
Start date	June 11, 2018
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03674125` - Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection	Phase 1
Completed	`NCT00978497` - Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection	Phase 2
Completed	`NCT00170131` - MMF Influence on HCV Viral Evolution After Liver Transplantation	Phase 4
Completed	`NCT04008927` - A Community-based Intervention Among Active Drug Users in Montpellier	N/A
Active, not recruiting	`NCT04044586` - HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
Completed	`NCT01958281` - Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency	Phase 2
Completed	`NCT02533427` - Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol	Phase 1
Completed	`NCT02783976` - Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
Withdrawn	`NCT04309734` - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects	Phase 1/Phase 2
Completed	`NCT01965535` - Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection	Phase 2
Completed	`NCT00768690` - A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333	Phase 1
Completed	`NCT00743795` - Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection	Phase 2
Withdrawn	`NCT04235049` - Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)	Phase 4
Terminated	`NCT00401947` - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection	Phase 2
Completed	`NCT00959699` - A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)	Phase 2
Completed	`NCT00623649` - Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection	Phase 1
Completed	`NCT00221624` - Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients	Phase 3
Completed	`NCT04134767` - Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)	N/A
Completed	`NCT02402452` - Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment	Phase 1
Completed	`NCT00909636` - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet	Phase 1